Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF NOVEMBER 05, 2020 SAM #6916
SOURCES SOUGHT

99 -- NIAID HIV and Other Infectious Diseases Clinical Research Support Services (CRSS)

Notice Date

11/3/2020 8:12:19 AM
 

Notice Type

Sources Sought
 

NAICS

541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
 

Contracting Office

NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
 

ZIP Code

20892
 

Solicitation Number

HHS-NIH-NIAID-75N93021R00001
 

Response Due

11/18/2020 12:00:00 PM
 

Archive Date

12/03/2020
 

Point of Contact

Rosemary Gomes, Phone: 2406695374, Michelle Scala, Phone: 2406695156
 

E-Mail Address

Rosemary.Gomes@nih.gov, mscala@niaid.nih.gov
(Rosemary.Gomes@nih.gov, mscala@niaid.nih.gov)
 

Description

The purpose of this Research and Development (R&D) Sources Sought Notice is to discern whether or not there are other contractors, including small or small disadvantaged businesses, capable of and interested in performing the work described herein. The NIAID does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted.� As a result of this R&D Sources Sought Notice, the NIAID may issue a Request for Proposals (RFP) if it is deemed necessary and appropriate. THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NIAID shall arise as a result of a response to this Sources Sought Notice or the NIAID�s use of such information as either part of our evaluation process or in developing specifications of any subsequent requirement. At this time, the complexity as well as quantity of requirements for support services for ACTIV- 2 have significantly increased based on �real time� clinical trial implementation data as well as evolving scientific requirements.� Specifically, the following significant increases of ACTIV-2 key clinical trial activity drivers have transpired since July 10,2020: Number of sites � over 346% increase in the number of Phase 2 sites (41 to 183) and over 317% increase in the number of Phase 3 sites (96 to 400); Number of screened patients � over 13% increase for Phase 2 screened patients (2,201 to 2,492) and over 57% increase in Phase 3 screened patients (8,901 to 14,000); Number of enrolled patients � over 33% increase for Phase 2 enrolled patients (1,320 to 1,760) and over 87% increase in Phase 3 enrolled/completed patients (5,340 to 10,000); Monitoring requirements � over 33% increase in Phase 2 monitoring requirements and over 67% increase in Phase 3 monitoring; The period of study is extended from December 31, 2021 to May 31, 2022. As a result of these increases in clinical trial support activities, the Government will require additional support to address these needs. The objective of this acquisition is to procure 360 FTEs to be delivered to the Government during the period March 1, 2021 through May 31, 2022. These additional resources are needed to provide the support as listed above.
 

Web Link

SAM.gov Permalink
(https://beta.sam.gov/opp/95fe80f661b94420920c09f74c7084fe/view)
 

Place of Performance

Address: Rockville, MD 20852, USA

Zip Code: 20852

Country: USA
 

Record

SN05845252-F 20201105/201103230144 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |